Document:

Exhibit
10.12

 

FIRST
AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT

 

This
First Amendment (“First Amendment”) to Exclusive License Agreement effective as of Dec,. 11 2020 (“First Amendment
Effective Date”) is by and between: EISAI INC., with its principal office at 100 Tice Blvd., Woodcliff Lake, NJ 07093,
United States of America (“Eisai”) and ALLARITY THERAPEUTICS A/S, with its principal office at Venlighedsvej I,
DK-2970 Hoersholm, Denmark (“Allarity”)(formerly Oncology Venture A/S), with reference to the following:

 

WITNESSETH:

 

WHEREAS,
as of July 6, 2017, the Parties entered into an Exclusive License Agreement, (the “Original Agreement”) relating to the cancer
drug E7449 (now Stenoparib (2X-121)), aPARP inhibitor,

 

WHEREAS,
Eisai and Allarity desire to amend certain provisions of the Original Agreement, in order to expand the Field, to reflect the modifications,
amendments, deletions and supplements set forth below.

 

NOW,
THEREFORE, in consideration of the foregoing premises, and the mutual promises and covenants of Parties set forth herein, the Parties
have agreed as follows:

 

1.
Definitions

 

Capitalized
terms used in this First Amendment and not defined herein shall have the meanings assigned thereto in the Original Agreement.

 

2.
Amendments and Agreements

 

		I)	In
Section 1.1 of the Original Agreement, the definition of “Field” is hereby amended and restated in its entirety as follows:

 

“Field”
shall mean as of the Effective Date, any and all preventative, therapeutic and/or diagnostic uses related to cancer or viral infection
in humans (including without limitation coronavirus vaccines and other treatments); it being understood and agreed that, effective upon
receipt by Allarity of rights to the CNS Field pursuant to any definitive agreement with Eisai as contemplated by Section 2.4, references
to “Fie]d” in this Agreement shall be deemed to include the CNS Field.

 

3.
Effect

 

This
First Amendment shall be effective from the First Amendment Effective Date.

 

4.
No Other Amendments

 

This
First Amendment shall be deemed to be part of and incorporated into the Original Agreement. Except as expressly set forth in this First
Amendment, all of the terms and conditions of the Original Agreement shall remain unchanged and are ratified, confirmed in all respects,
and remain in full force and effect.

 

5.
Counterparts

 

This
First Amendment may be executed in any number of counterparts, each of which shall be deemed an original and all of which taken together
shall be deemed to constitute one and the same instrument. An executed signature page of this First Amendment delivered by facsimile
transmission or by electronic mail in “portable document format” shall be as effective as an original executed signature page.

 

[Signature
Page Follows]

 

     

     

    

 

IN
WITNESS WHEREOF, the Parties hereto have executed this First Amendment through their duly authorized representatives and made effective
as of the First Amendment Effective Date.

 

	Allarity Therapeutics	 	A/S Eisai
	 	 	 
	By:	/s/
  James Cullum	 	By:	/s/
  Takashi Owa
	Name: 	James Cullum	 	Name: 	Takashi Owa
	Title:	Senior VP., Corporate Development	 	Title:	Chief Medicine Creation Officer Oncology Business Group
  Eisai Inc.
	 	 	 	 	 
	Date: 	December 11, 2020	 	Date: 	December 10, 2020

 

{Signature
Page to First Amendment to Exclusive License Agreement between OV and Eisai}Exhibit 4.1

 

	NUMBER	     UNITS

U-

 

SEE REVERSE FOR CERTAIN DEFINITIONS

 

CUSIP _______

 

PROJECT ENERGY REIMAGINED ACQUISITION CORP.

 

UNITS CONSISTING OF ONE CLASS A ORDINARY
SHARE AND ONE-HALF OF ONE

REDEEMABLE WARRANT, EACH WHOLE WARRANT ENTITLING THE HOLDER TO PURCHASE ONE CLASS A ORDINARY SHARE

 

THIS CERTIFIES THAT                     
is the owner of          Units of Project Energy Reimagined Acquisition Corp., a Cayman Islands
exempted company (the “Company”), transferable on the books of the Company in person or by duly authorized attorney
upon surrender of this certificate properly endorsed.

 

Each Unit (“Unit”)
consists of one Class A ordinary share, par value $0.0001 per share (“Ordinary Share”), of the Company
and one-half of one redeemable warrant (each whole warrant, a “Warrant”). Each whole Warrant entitles
the holder to purchase one Ordinary Share for $11.50 per share (subject to adjustment). Only whole Warrants are exercisable. Each
Warrant will become exercisable on the later of (i) thirty (30) days after the Company’s completion of a merger, share
exchange, asset acquisition, share purchase, reorganization or other similar business combination with one or more businesses (each a
 “Business Combination”), or (ii) twelve (12) months from the closing of the Company’s initial public
offering, and will expire unless exercised before 5:00 p.m., New York City Time, on the date that is five (5) years after the date
on which the Company completes its initial Business Combination, or earlier upon redemption or liquidation (the “Expiration
Date”). The Ordinary Shares and Warrants comprising the Units represented by this certificate are not transferable
separately prior to , 2021, unless J.P. Morgan Securities LLC and BofA Securities, Inc. elect to allow separate trading earlier,
subject to the Company’s filing of a Current Report on Form 8-K with the Securities and Exchange Commission containing an audited
balance sheet reflecting the Company’s receipt of the gross proceeds of the Company’s initial public offering and issuing
a press release announcing when separate trading will begin. No fractional Warrants will be issued upon separation of the Units and only
whole Warrants will trade. The terms of the Warrants are governed by a Warrant Agreement, dated as of , 2021 (the “Warrant
Agreement”), between the Company and Continental Stock Transfer & Trust Company, as Warrant Agent, and are subject
to the terms and provisions contained therein, all of which terms and provisions the holder of this certificate consents to by acceptance
hereof. Copies of the Warrant Agreement are on file at the office of the Warrant Agent at 1 State Street, 30th Floor,
New York, New York 10004, and are available to any Warrant holder on written request and without cost.

 

Upon consummation of a Business Combination, the
Units represented by this certificate will automatically separate into the Ordinary Shares and Warrants comprising such Units.

 

This certificate is not valid unless countersigned
by the Transfer Agent and registered by the Registrar of the Company.

 

This certificate shall be governed by and construed
in accordance with the internal laws of the State of New York.

 

Witness the facsimile signature of a duly authorized
signatory of the Company.

 

	 	 	 
	Authorized Signatory	 	Transfer Agent

 

     

     

    

 

PROJECT ENERGY REIMAGINED ACQUISITION CORP.

 

The Company will furnish without charge to each
unitholder who so requests, a statement of the powers, designations, preferences and relative, participating, optional or other special
rights of each class of equity or series thereof of the Company and the qualifications, limitations, or restrictions of such preferences
and/or rights.

 

The following abbreviations, when used in the
inscription on the face of this certificate, shall be construed as though they were written out in full according to applicable laws or
regulations:

 

	 	 	 	 	 	 	 	 	 	 	 
	TEN COM     —     as tenants in common	 	UNIF GIFT MIN ACT	 	—	 	
	 	Custodian	 	

	TEN ENT       —     as tenants by the entireties	 	 	 	 	 	    (Cust)    	 	 	 	      (Minor)      
	 	 	 	 
	
    JT TEN           —    as joint tenants with right of survivorship and not as tenants in

    common
	 	 	 	 	 	under Uniform Gifts to Minors Act
	 	 	 	 	 	 	

    (State)

 

Additional abbreviations may also be used though
not in the above list.

 

For value received,                     
hereby sell, assign and transfer unto

 

(PLEASE INSERT SOCIAL SECURITY OR OTHER IDENTIFYING
NUMBER OF ASSIGNEE)

 

(PLEASE PRINT OR TYPEWRITE NAME AND ADDRESS, INCLUDING
ZIP CODE, OF ASSIGNEE)

 

Units represented by the within certificate,
and do hereby irrevocably constitute and appoint

 

Attorney to transfer the said Units on the books of the within
named Company with full power of substitution in the premises.

 

Dated

 

	 	

	 	 
	 	Notice: The signature to this assignment must correspond with the name as written upon the face of the certificate in every particular, without alteration or enlargement or any change whatever.

 

	Signature(s) Guaranteed:

 

     

     

    

 

	
	 
	THE SIGNATURE(S) MUST BE GUARANTEED BY AN ELIGIBLE GUARANTOR INSTITUTION (BANKS, STOCKBROKERS, SAVINGS AND LOAN ASSOCIATIONS AND CREDIT UNIONS WITH MEMBERSHIP IN AN APPROVED SIGNATURE GUARANTEE MEDALLION PROGRAM, PURSUANT TO S.E.C. RULE 17Ad-15 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED (OR ANY SUCCESSOR RULE)).	 

 

As more fully described
in, and subject to the terms and conditions described in, the Company’s final prospectus for its initial public offering dated                   ,
2021, the holder(s) of this certificate shall be entitled to receive a pro-rata portion of certain funds held in the trust account
established in connection with the Company’s initial public offering only in the event that (i) the Company redeems the Ordinary
Shares sold in its initial public offering and liquidates because it does not consummate an initial Business Combination within the time
period set forth in the Company’s Amended and Restated Memorandum and Articles of Association, as the same may be amended from time
to time, or (ii) if the holder(s) properly redeem for cash his, her or its respective Ordinary Shares included in the Units
represented by this certificate in connection with (x) a tender offer (or proxy solicitation, solely in the event the Company seeks
shareholder approval of the proposed initial Business Combination ) setting forth the details of a proposed Business Combination or (y) a
shareholder vote to amend the Company’s Amended and Restated Memorandum and Articles of Association, as the same may be amended
from time to time, (A) to modify the substance or timing of the Company’s obligation to allow redemption in connection with
our initial Business Combination or to redeem 100% of the Ordinary Shares if it does not consummate an initial Business Combination within
the time period set forth in the Company’s Amended and Restated Memorandum and Articles of Association or (B) with respect
to any other material provisions relating to shareholders’ rights or pre-initial Business Combination activity. In no other circumstances
shall the holder(s) have any right or interest of any kind in or to the trust account.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}]]